Catalyst Pharmaceuticals to Participate in the Barclays 27th Annual Global Healthcare Conference
Catalyst Pharmaceuticals (NASDAQ: CPRX), a commercial-stage biopharmaceutical company specializing in rare and difficult-to-treat diseases, has announced its participation in the Barclays 27th Annual Global Healthcare Conference.
The company's presentation is scheduled for Tuesday, March 11, 2025, at 1:00 PM ET in Miami, Florida. Richard J. Daly, President and CEO, will lead the presentation along with other management team members.
Investors and interested parties can access the presentation webcast through the Investors section of www.catalystpharma.com. A replay will remain available for a minimum of 30 days following the event.
Catalyst Pharmaceuticals (NASDAQ: CPRX), un'azienda biofarmaceutica in fase commerciale specializzata in malattie rare e difficili da trattare, ha annunciato la sua partecipazione alla 27ª Conferenza Globale Annuale sulla Salute di Barclays.
La presentazione dell'azienda è programmata per martedì 11 marzo 2025, alle 13:00 ET a Miami, Florida. Richard J. Daly, Presidente e CEO, guiderà la presentazione insieme ad altri membri del team di gestione.
Gli investitori e le parti interessate possono accedere alla trasmissione in diretta della presentazione attraverso la sezione Investitori di www.catalystpharma.com. Una registrazione sarà disponibile per un minimo di 30 giorni dopo l'evento.
Catalyst Pharmaceuticals (NASDAQ: CPRX), una empresa biofarmacéutica en etapa comercial especializada en enfermedades raras y difíciles de tratar, ha anunciado su participación en la 27ª Conferencia Global Anual de Salud de Barclays.
La presentación de la empresa está programada para el martes 11 de marzo de 2025, a la 1:00 PM ET en Miami, Florida. Richard J. Daly, Presidente y CEO, liderará la presentación junto con otros miembros del equipo directivo.
Los inversores y partes interesadas pueden acceder a la transmisión en vivo de la presentación a través de la sección de Inversores de www.catalystpharma.com. Una repetición estará disponible durante un mínimo de 30 días después del evento.
카탈리스트 제약 (NASDAQ: CPRX), 희귀하고 치료하기 어려운 질병에 전문화된 상업 단계의 생명공학 회사가 바클레이스 제27회 연례 글로벌 헬스케어 컨퍼런스에 참가한다고 발표했습니다.
회사의 발표는 2025년 3월 11일 화요일 오후 1시 ET에 플로리다주 마이애미에서 예정되어 있습니다. 리차드 J. 데일리 CEO가 발표를 이끌며 다른 경영진과 함께합니다.
투자자 및 관심 있는 당사자는 www.catalystpharma.com의 투자자 섹션을 통해 발표 웹캐스트에 접근할 수 있습니다. 이벤트 후 최소 30일 동안 재생이 가능합니다.
Catalyst Pharmaceuticals (NASDAQ: CPRX), une entreprise biopharmaceutique en phase commerciale spécialisée dans les maladies rares et difficiles à traiter, a annoncé sa participation à la 27ème Conférence Annuelle Mondiale sur la Santé de Barclays.
La présentation de l'entreprise est prévue pour mardi 11 mars 2025 à 13h00 ET à Miami, en Floride. Richard J. Daly, Président et CEO, dirigera la présentation avec d'autres membres de l'équipe de direction.
Les investisseurs et les parties intéressées peuvent accéder à la diffusion en direct de la présentation via la section Investisseurs de www.catalystpharma.com. Un enregistrement sera disponible pendant au moins 30 jours après l'événement.
Catalyst Pharmaceuticals (NASDAQ: CPRX), ein biopharmazeutisches Unternehmen in der kommerziellen Phase, das sich auf seltene und schwer zu behandelnde Krankheiten spezialisiert hat, hat seine Teilnahme an der 27. jährlichen globalen Gesundheitskonferenz von Barclays angekündigt.
Die Präsentation des Unternehmens ist für Dienstag, den 11. März 2025, um 13:00 Uhr ET in Miami, Florida, geplant. Richard J. Daly, Präsident und CEO, wird die Präsentation zusammen mit anderen Mitgliedern des Management-Teams leiten.
Investoren und interessierte Parteien können über den Investorenbereich von www.catalystpharma.com auf den Webcast der Präsentation zugreifen. Eine Wiederholung wird mindestens 30 Tage nach der Veranstaltung verfügbar sein.
- None.
- None.
CORAL GABLES, Fla., March 04, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that Richard J. Daly, President and CEO of Catalyst, along with other members of Catalyst's management team, will participate in the upcoming Barclays 27th Annual Global Healthcare Conference on Tuesday, March 11, 2025 being held in Miami, Florida.
Presentation Details
Date: Tuesday, March 11, 2025
Presentation: 1:00 PM ET
Webcast Link
The webcast will be available under the Investors section on the Company's website, www.catalystpharma.com, and a replay will be available for at least 30 days.
About Catalyst Pharmaceuticals
Catalyst Pharmaceuticals, Inc. (Nasdaq: CPRX) is a biopharmaceutical company committed to improving the lives of patients with rare diseases. With a proven track record of bringing life-changing treatments to the market, we focus on in-licensing, commercializing, and developing innovative therapies. Guided by our deep commitment to patient care, we prioritize accessibility, ensuring patients receive the care they need through a comprehensive suite of support services designed to provide seamless access and ongoing assistance. Catalyst maintains a well-established U.S. presence while actively seeking to expand its global commercial footprint through strategic partnerships. Catalyst, headquartered in Coral Gables, Fla., was recognized on the Forbes 2025 list as one of America's Most Successful Mid-Cap Companies and on the 2024 Deloitte Technology Fast 500™ list as one of North America’s Fastest-Growing Companies.
For more information, please visit Catalyst's website at www.catalystpharma.com.
Forward-Looking Statements
This press release contains forward-looking statements, as that term is defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which may cause Catalyst's actual results in future periods to differ materially from forecasted results. A number of factors, including those factors described in Catalyst's Annual Report on Form 10-K for the fiscal year 2024 and its subsequent filings with the U.S. Securities and Exchange Commission (“SEC”), could adversely affect Catalyst. Copies of Catalyst's filings with the SEC are available from the SEC, may be found on Catalyst's website, or may be obtained upon request from Catalyst. Catalyst does not undertake any obligation to update the information contained herein, which speaks only as of this date.
Source: Catalyst Pharmaceuticals, Inc.
FAQ
When is Catalyst Pharmaceuticals (CPRX) presenting at the Barclays Healthcare Conference 2025?
How can investors watch Catalyst Pharmaceuticals' (CPRX) Barclays conference presentation?
Who will represent CPRX at the Barclays Global Healthcare Conference 2025?
What type of diseases does Catalyst Pharmaceuticals (CPRX) focus on?
